VivoSeq
Other

Stress Urinary Incontinence

25

Pipeline Programs↗

10

Active Trials↗

13

Companies Involved↗

Stress urinary incontinence is an emerging landscape with 25 programs across 13 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Lundbeck, Pfizer. 2 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

22/100

Mech. Concentration

33/100

Completion Rate

84/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 1Lundbeck logo

Lundbeck

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.

1 program

Phase 2Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

4%ALL OTHERSCell therapy14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 97% of 34 pipeline programs.

Analysis

Trial Status

55

clinical trials

Completed36 · 65%
Withdrawn5 · 9%
Not yet recruiting4 · 7%
Recruiting4 · 7%
Unknown status2 · 4%
Active, not recruiting2 · 4%
Other2 · 4%

Clinical Trials

Trial Activity

55 trials

CHM for Female Stress Urinary Incontinence
Recruiting·HHong Kong Baptist University·N/A·NCT06855602·15 enrolled
A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Stress Urinary Incontinence
Recruiting·CCorewell Health East·Preclinical·NCT04133675·110 enrolled
A Long Term Prospective Observational Post Market Clinical Follow-Up (PMCF) Registry of Ethicon Gynecare Pelvic Mesh Products for The Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse
Recruiting·EEthicon, Inc.·N/A·NCT04829175·1,000 enrolled
A Long Term Prospective Post Market Clinical Follow-up (PMCF) of the GYNECARE TVT ABBREVO® Continence System for the Treatment of Stress Urinary Incontinence
Recruiting·EEthicon, Inc.·N/A·NCT04829357·195 enrolled
A Long Term Prospective Post Market Clinical Follow-up (PMCF) of the GYNECARE TVT EXACT® Continence System for the Treatment of Stress Urinary Incontinence
Active, not recruiting·EEthicon, Inc.·N/A·NCT04829994·198 enrolled
A Pilot Study to Evaluate the Anabolic Effect of Testosterone on Muscles of the Pelvic Floor in Older Women With Stress Urinary Incontinence
Active, not recruiting·BBrigham and Women's Hospital·Phase 2·NCT06111209·30 enrolled
The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence
Not yet recruiting·HHanoi Medical University·N/A·NCT07186985·115 enrolled
Impact of Virtual Reality Pelvic Floor Training on Postpartum Stress Urinary Incontinence
Not yet recruiting·—·N/A·NCT07455838·50 enrolled
Effect of Different Pelvic Floor Loading Techniques on Women With Stress Urinary Incontinence
Not yet recruiting·CCairo University·Preclinical·NCT07661264·40 enrolled
Additive Role of Low-intensity Extracorporeal Shock Wave Therapy to Kegel's Exercise in Management of Female Stress Urinary Incontinence : A Prospective Randomized Study
Not yet recruiting·SSuez Canal University·Preclinical·NCT07663968·84 enrolled
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
Completed·Pfizer logoPfizer·Phase 2·NCT01042236·22 enrolled
A Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Completed·Taiho Pharmaceutical Co., Ltd. logoTaiho Pharmaceutical Co., Ltd.·Phase 1·NCT02562807·16 enrolled
Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
Completed·Eli Lilly logoEli Lilly·Phase 3·NCT00191204·363 enrolled
Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.
Completed·Eli Lilly logoEli Lilly·Phase 4·NCT00190905·4,000 enrolled
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00190606·200 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)